Research programme: interleukin-8 antagonists - Sanofi-Aventis/Millennium

Drug Profile

Research programme: interleukin-8 antagonists - Sanofi-Aventis/Millennium

Latest Information Update: 04 Jun 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals; sanofi-aventis
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action Interleukin 8 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Reperfusion injury; Unspecified

Most Recent Events

  • 14 May 2008 Millennium Pharmaceuticals has been acquired by Takeda
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 03 Feb 2004 No development reported - Preclinical for Reperfusion injury in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top